|
IMS Health's full text, in-depth reports on major pharmaceutical
companies worldwide.
IPCP reports cover each company's activity in finance, research and
development, product portfolio, historical development and major
events.
Each year key organisations that shape the pharmaceutical industry
are profiled and updated to include the latest commercial
information. Currently (December 2006) about 95 of the most
significant pharmaceutical companies are covered.
The database contains only the most recent profile for each company
covered by IMS. There is no archive of previous years' profiles.
For business analysts and everyone engaged in pharmaceutical
research, development and production, IPCP is a unique source of
reliable, evaluated information. Its strategic and competitive
analysis of the worldwide pharma industry includes interviews with
key company executives wherever possible, gathering inside
information unobtainable elsewhere. The views of independent
financial analysts are included in many reports, to add breadth of
viewpoint.
Use IPCP to:
- ascertain the strengths and weaknesses of competitors
- analyse sales and financial performance by business and
geographic sectors
- discover what is the R&D pipeline of other companies
- get a clear historical perspective on a company of specific
interest
- collect up-to-date analyses of leading products within each
field.
- find the latest commercial intelligence on a company such as
GlaxoSmithKline
Sources:
IMS Health collects data for IPCP from the following principal
sources: its own in-house information from IMS services, interviews
with executives within the profiled companies independent financial
analysts, press conferences and investor meetings.
Published sources include annual reports, analyst reports, newswires
and the trade press. Coverage in IPCP includes a wide range of
companies - both large and small, private and public, national and
multinational within the international arena.
AN - Accession number & update
00115239 20060804.
CO - Company name
BRISTOL-MYERS SQUIBB.
SO - Source
IMSworld Publications, Ltd, March 03 2006.
OC - Occurrences
PARAGRAPH
CO (1).
LE - Length
451,645 Characters, approximately 266 PC screens
Number of TX paragraphs: (62).
TC - Table of contents
STRATEGY STATEMENT : INTRODUCTION TX(1)
STRATEGY STATEMENT : REGIONAL STRATEGY TX(2)
STRATEGY STATEMENT : THERAPEUTIC FOCUS TX(3)
STRATEGY STATEMENT : R&D TX(4)
STRATEGY STATEMENT : LICENSING TX(5)
STRATEGY STATEMENT : PATENT ISSUES TX(6)
STRATEGY STATEMENT : FUTURE PROSPECTS TX(7)
STRATEGY STATEMENT : IMPACT OF FUTURE EVENTS TX(8)
STRATEGY STATEMENT : COMPANY INTERVIEW TX(9)
STRATEGY STATEMENT : COMPANY INTERVIEW TX(10)
(...)
YR - Publication year
2006.
DT - Publication date
20060303.
TX - Text
1 OF 62
STRATEGY STATEMENT : INTRODUCTION
BMS Looks to Renewed Growth in 2007
Bristol-Myers Squibb (BMS) markets ethical drugs, medical
devices, has had various problems in recent years: a major drug
in R&D had serious side-effects and has now been sidelined, there
was an investigation into accounting irregularities, and now many
of its products are facing or have experienced patent expiry,
with some analysts wondering if lost sales can be made up by
increasing sales of other marketed products and the launch of new
ones. BMS has now fallen out of the world's top five
pharmaceutical corporate groups, to be ranked number nine in
2004, according to IMS.
In 2003, BMS' board of directors approved CEO Peter Dolan's
five-year plan, backing the recovery program he has developed.
This plan involves return-on-investment measurements across the
company, a revamp of internal controls and costs, and the launch
of new drugs to boost sales. In addition, there is now an
increasing focus away from general primary care drugs and towards
high-tech products which fulfill significant unmet need in
serious illnesses, predominantly treated by specialists. Many of
its new products and products nearing the market (such as Abilify
and Orencia) are geared towards specialists than general
practitioners. Because of this shift in product focus, BMS is
undergoing a major shift in strategy, moving away from selling to
mass-market primary care physicians in favor of selling to
specialists, such as oncologists and psychiatrists. A company
selling to specialists needs fewer sales people, which should
mean better margins. In October 2004, BMS announced plans to lay
off 500 salespeople.
(...)
2 OF 62
STRATEGY STATEMENT : REGIONAL STRATEGY
Aims to Boost Global Presence
BMS has sought to bolster its global pharmaceutical business in
markets, especially China and Latin America. It also hopes to
expand its presence in Japan, with growth driven by new oncology
and antiviral therapies. BMS is looking to achieve sales of over
Yen100 billion (around $950 million). At the moment, BMS's
business is US-biased, with 55% of total sales made in the USA in
2004 (compared to 68% in 2001). A breakdown by geographical
region for 2005 is not yet available.
3 OF 62
STRATEGY STATEMENT : THERAPEUTIC FOCUS
Patent Exposure is Major Problem for BMS
According to IMS, main therapeutic areas for BMS in terms of
sales inhibitors, HIV antivirals, "all other antineoplastics"
(class L1X) and vinca alkaloids. BMS is currently feeling the
impact of patent expirations. It has recently lost exclusivity
for some important products and in the 2004-2008 period eight
major drugs will see patent expiry: Pravachol, Paraplatin, Zerit,
Glucovance, Glucophage XR, Cefzil, Videx and Tequin.
Paraplatin, Glucophage XR, Glucovance and Videx are already open
to generic competition, as are the cancer drugs Taxol
(paclitaxel) and Paraplatin (carboplatin), and the ACE inhibitor
Monopril (fosinopril). Meanwhile generic competition is on the
horizon for Zerit (from 2007 in some markets, 2008 in the USA),
Cefzil (patents outside the US began expiring in 2004 and the
patent expired in the USA in December 2005), Tequin (December
2007 in the USA and 2007 and later outside) and Pravachol
(already expired in some markets, with expiry in the USA set for
April 2006).
(..)
CP - Copyright statement
Copyright (c) 2006 IMSworld Publications, Ltd. All rights
reserved.
Labels/description Example
AN Accession number 1_: 00115239.AN.
& update - see Limit options -
CO Company name 2_: BRISTOL-MYERS$.CO.
- New profiles (completely
revised once per year) 3_: NEW=YES
- Mid-year updates 4_: UPDATE=YES
- see also Notes -
SO Source - the same for all documents -
OC Occurrences - display only -
LE Length - see Limit options -
TC Table of contents 5_: REGIONAL ADJ STRATEGY.TC.
YR Year of publication
YEAR= Publication year 6_: YEAR=2006
- see also Limit options -
DT Publication date
DATE= Publication date 7_: DATE=20060303
MONTH= Publication month 8_: MONTH=200603
- see also Limit options -
TX Text 9_: ETHICAL WITH DRUGS.TX.
CP Copyright statement - the same for all documents -
1_: SWITZERLAND.CN.
DATE Publication date 2_: ..L 1 DATE>20060101
MONTH Publication month 3_: ..L 1 MONTH=200603
YEAR Publication year 4_: ..L 1 YEAR<2007
UDATE Update date 5_: ..L 1 UDATE>20051231
UMONTH Update month 6_: ..L 1 UMONTH>200606
By paragraph: Company _: ..P CO, TX(1,5) 1-3
SHORT AN CO SO OC LE YR CP
MEDIUM AN CO SO OC LE TC YR CP
LONG AN CO SO OC LE TC YR CP HITS
ALL AN CO SO OC LE TC YR TX CP
KWIC Context of search terms in the TX paragraphs
HITS All paragraphs where search terms occur
FREE AN CO SO OC LE TC YR DT CP
_: ..P LONG 3.
Differences between new and updated profiles:
Each company profile is completely revised each year and resupplied
to DataStar. These can be identified with the search 'NEW=YES'. In
addition, one or more updates can be sent throughout the rest of the
year. These updates are themselves complete profiles. The
differences between the most recent updated profile and the previous
version are listed in the first TX section of the profile - e.g.:
CO NOVARTIS; UPDATE.
TC PROFILE UPDATES TX(1) <--
STRATEGY STATEMENT : INTRODUCTION TX(2)
STRATEGY STATEMENT : BACKGROUND TX(3)
STRATEGY STATEMENT : M&A ACTIVITY TX(4)
STRATEGY STATEMENT : REGIONAL STRATEGY TX(5)
STRATEGY STATEMENT : THERAPEUTIC FOCUS TX(6)
STRATEGY STATEMENT : R&D TX(7)
STRATEGY STATEMENT : FUTURE PROSPECTS TX(8)
STRATEGY STATEMENT : IMPACT OF FUTURE EVENTS TX(9)
FINANCIAL REVIEW TX(10)
FINANCIAL REVIEW : LATEST RESULTS TX(11)
FINANCIAL REVIEW : ANALYST COMMENT
(...)
TX 1 OF 63
PROFILE UPDATES
Sections updated since last update 25th August 2005:
Date Section Details
2005 Statement
Analyst Comment Overview, tables
Product Zelmac/Zelnorm,
Portfolio Sandimmun/Neoral, Certican,
Glivec, Femara, Myfortic,
Lotrel, Lescol, Diovan,
Tegretol, Clozaril, Trileptal,
Exelon, Elidel, Lamisil,
Sandostatin, Voltaren,
Miacalcic, Zometa/Aclasta,
Foradil, Zaditen, Xolair,
Visudyne, Enablex, Prexige,
Generics.
R&D Profile Introduction, LAF 237,
Lucentis, AMN 107, Exjade, SPP
100, Omnitrope, indacaterol,
LDT 600, SBR 759, NM 100060,
CAD 106, Discontinued
Licensing Tables R&D, General Research Collaborations.
By checking this section, the user will know that they only need
display the 'Statement', 'Analyst Comment', 'Product Portfolio',
'R&D Profile' and 'Licensing Tables' sections of the profile.
Updated profiles are identified by the word 'UPDATE' which will
appear at the end of the CO paragraph. These can be retrieved with
the search 'UPDATE=YES'.
Searching in TX paragraphs:
Use WITH (same sentence) and SAME (same TX paragraph) operators for
relevance of retrieval.
Search Options:
..SET PLURALS ON and ..SET MEDWORD ON can be selected in IPCP
Guides:
The guide to IMS Company Profiles is available online in the BASE
database - search as BASE-IPCP.
Back to the Datasheet Index Page
© 2008 Dialog DataStar
|